Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.32 |
| ▸ | KDM4A | O75164 | 1/20 | 0.32 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3613143 | 1.00 | LMNA (0.50) | LMNAKDM4CKDM4APHF8KDM2A | |
| SCHEMBL3616255 | 1.00 | LMNA (0.50) | LMNAKDM4CKDM4APHF8KDM2A | |
| SCHEMBL3098215 | 1.00 | LMNA (0.50) | LMNAKDM4CKDM4APHF8KDM2A | |
| SCHEMBL3100626 | 1.00 | LMNA (0.50) | LMNAKDM4CKDM4APHF8KDM2A | |
| SCHEMBL4609703 | 1.00 | LMNA (0.50) | LMNAKDM4CKDM4APHF8KDM2A | |
| SCHEMBL3626685 | 1.00 | LMNA (0.50) | LMNAKDM4CKDM4APHF8KDM2A | |
| SCHEMBL316477 | 1.00 | — | — | |
| SCHEMBL3624160 | 1.00 | LMNA (0.50) | LMNAKDM4CKDM4APHF8KDM2A | |
| SCHEMBL4610382 | 1.00 | LMNA (0.50) | LMNAKDM4CKDM4APHF8KDM2A | |
| SCHEMBL3620802 | 1.00 | LMNA (0.50) | LMNAKDM4CKDM4APHF8KDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024579-B2 | Curable liquid composition, particulate filler, and compound | TOKYO OHKA KOGYO CO., LTD. (JP) | 2024-07-02 | — | — | US | disclosed |
| WO-2024122572-A1 | WAVELENGTH CONVERSION FILM-FORMING COMPOSITION AND FUSED THIOPHENE COMPOUND | 日産化学株式会社 | 2024-06-13 | — | — | WO | disclosed |
| US-20240045330-A1 | NEGATIVE PHOTOSENSITIVE COMPOSITION AND PATTERN FORMATION METHOD | TOKYO OHKA KOGYO CO., LTD. (JP) | 2024-02-08 | — | — | US | disclosed |
| US-11718758-B2 | Aqueous dispersion of colored particles | MITSUBISHI PENCIL COMPANY, LIMITED (JP) | 2023-08-08 | — | — | US | disclosed |
| US-20230236505-A1 | NEGATIVE PHOTOSENSITIVE RESIN COMPOSITION, PATTERN FORMATION METHOD, AND LAMINATED FILM | SAN-APRO LTD. (JP) | 2023-07-27 | — | — | US | disclosed |
| EP-3725854-B1 | COLORED PARTICLE AQUEOUS DISPERSION | MITSUBISHI PENCIL CO (JP) | 2023-07-05 | — | — | EP | disclosed |
| US-11542397-B2 | Liquid composition, quantum dot-containing film, optical film, light-emitting display element panel, and light-emitting display device | TOKYO OHKA KOGYO CO., LTD. (JP) | 2023-01-03 | — | — | US | disclosed |
| CN-113264856-B | Sulfonium salt, photoacid generator, and photosensitive composition | 东京应化工业株式会社 | 2022-11-22 | — | — | CN | disclosed |
| US-11370751-B2 | Sulfonium salt, heat- or photo-acid generator, heat- or photo-curable composition, and cured product thereof | SAN APRO LTD. (JP) | 2022-06-28 | — | — | US | disclosed |
| US-20220195097-A1 | CURABLE LIQUID COMPOSITION, PARTICULATE FILLER, AND COMPOUND | TOKYO OHKA KOGYO CO., LTD. (JP) | 2022-06-23 | — | — | US | disclosed |
| US-7799954-B2 | Dicarbonyl derivatives and methods of use | ABRAXIS BIOSCIENCE, LLC (US) | 2010-09-21 | — | — | US | disclosed |
| EP-2125694-A2 | DICARBONYL DERIVATIVES AND METHODS OF USE | Abraxis BioScience, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| EP-1976505-A1 | COMBRETASTATIN DERIVATIVES AND RELATED THERAPEUTIC METHODS | Abraxis BioScience, Inc. (US) | 2008-10-08 | — | — | EP | disclosed |
| US-20080146586-A1 | DICARBONYL DERIVATIVES AND METHODS OF USE | ABRAXIS BIOSCIENCE (US) | 2008-06-19 | — | — | US | disclosed |
| WO-2008064060-A2 | DICARBONYL DERIVATIVES AND METHODS OF USE | ABRAXIS BIOSCIENCE, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2007059118-A1 | COMBRETASTATIN DERIVATIVES AND RELATED THERAPEUTIC METHODS | ABRAXIS BIOSCIENCE, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| US-5650430-A | Radicicol derivatives, their preparation and their anti-tumor activity | SANKYO COMPANY, LIMITED (JP) | 1997-07-22 | — | — | US | disclosed |
| US-5597846-A | ESTERS OF RADICICOL | SANKYO COMPANY, LIMITED (JP) | 1997-01-28 | — | — | US | disclosed |
| WO-1991018905-A1 | RADICICOL DERIVATIVES, THEIR PREPARATION AND THEIR ANTI-TUMOR ACTIVITY | SANKYO COMPANY LIMITED (JP) | 1991-12-12 | — | — | WO | disclosed |
| EP-0460950-A1 | Radicicol derivatives, their preparation and their anti-tumour activity | Sankyo Company Limited (JP) | 1991-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146586-A1 | DICARBONYL DERIVATIVES AND METHODS OF USE | AADAC, DCK, MLYCD | LMNA 2382/4885KDM4C 483/4885KDM4A 482/4885 |
| US-11370751-B2 | Sulfonium salt, heat- or photo-acid generator, heat- or photo-curable composition, and cured product thereof | TST, MPST, ASIC1 | LMNA 4781/4885KDM4C 3545/4885KDM4A 3210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.